Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells

被引：27
|
作者：
Del Re, Marzia [1 ]
Arrigoni, Elena [1 ]
Restante, Giuliana [1 ]
Passaro, Antonio [2 ]
Rofi, Eleonora [1 ]
Crucitta, Stefania [1 ]
De Marinis, Filippo [2 ]
Di Paolo, Antonello [1 ]
Danesi, Romano [1 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Clin Pharmacol & Pharmacogenet Unit, Pisa, Italy
[2] European Inst Oncol, Div Thorac Oncol, Milan, Italy
来源：
STEM CELLS | 2018年 / 36卷 / 05期
关键词：
Cancer stem cells; Treatment resistance; Tyrosine kinase inhibitors; Biomarkers; Tumor heterogeneity; GROWTH-FACTOR-RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; EGFR-TKI; DRUG-RESISTANCE; DNA METHYLATION; GENETIC-HETEROGENEITY; TUMOR HETEROGENEITY; T790M MUTATION; PROTEIN-KINASE;
D O I：
10.1002/stem.2787
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Among the potential mechanisms involved in resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer, the manifestation of stem-like properties in cancer cells seems to have a crucial role. Alterations involved in the development of TKI resistance may be acquired in a very early phase of tumorigenesis, supporting the hypothesis that these aberrations may be present in cancer stem cells (CSCs). In this regard, the characterization of tumor subclones in the initial phase and the identification of the CSCs may be helpful in planning a specific treatment to target selected biomarkers, suppress tumor growth, and prevent drug resistance. The aim of this review is to elucidate the role of CSCs in the development of resistance to TKIs and its implication for the management of patients.
引用
收藏
页码：633 / 640
页数：8
相关论文
共 50 条
  • [21] Tyrosine-kinase inhibitors for non-small cell lung cancer - addition - EML
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 293 - 301
  • [22] Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Fujino, Toshio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (03) : 229 - 249
  • [23] Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
    Nguewa, Paul A.
    Calvo, Alfonso
    Pullamsetti, Soni Savai
    Banat, Gamal Andre
    Grimminger, Friedrich
    Savai, Rajkumar
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (01) : 61 - 74
  • [24] Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
    Ohashi, Yoshimi
    Okamura, Mutsumi
    Katayama, Ryohei
    Fang, Siyang
    Tsutsui, Saki
    Akatsuka, Akinobu
    Shan, Mingde
    Choi, Hyeong-Wook
    Fujita, Naoya
    Yoshimatsu, Kentaro
    Shiina, Isamu
    Yamori, Takao
    Dan, Shingo
    ONCOTARGET, 2018, 9 (02) : 1641 - 1655
  • [25] Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer
    Dimou, Anastasios
    Nasarre, Cecile
    Peterson, Yuri K.
    Pagano, Rose
    Gooz, Monika
    Nasarre, Patrick
    Drabkin, Harry A.
    Armeson, Kent E.
    Gibney, Barry C.
    Gemmill, Robert M.
    Denlinger, Chadrick E.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (02): : 463 - 473
  • [26] Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
    Nurwidya, Fariz
    Takahashi, Fumiyuki
    Murakami, Akiko
    Kobayashi, Isao
    Kato, Motoyasu
    Shukuya, Takehito
    Tajima, Ken
    Shimada, Naoko
    Takahashi, Kazuhisa
    RESPIRATORY INVESTIGATION, 2014, 52 (02) : 82 - 91
  • [27] Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
    Liao, Zi-Xian
    Huang, Kuo-Yen
    Kempson, Ivan M.
    Li, Hsin-Jung
    Tseng, S. -Ja
    Yang, Pan-Chyr
    JOURNAL OF CONTROLLED RELEASE, 2020, 324 : 482 - 492
  • [28] Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Iommelli F.
    De Rosa V.
    Fonti R.
    Del Vecchio S.
    Clinical and Translational Imaging, 2014, 2 (1) : 43 - 53
  • [29] EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
  • [30] Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Li
    Wang, Wen
    ONCOLOGY REPORTS, 2021, 45 (01) : 13 - 28
12345